BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/21/2017 7:51:53 AM | Browse: 1268 | Download: 1276
 |
Received |
|
2017-06-04 13:43 |
|
Peer-Review Started |
|
2017-06-06 07:40 |
|
To Make the First Decision |
|
2017-06-22 06:00 |
|
Return for Revision |
|
2017-06-27 10:37 |
|
Revised |
|
2017-07-03 11:58 |
|
Second Decision |
|
2017-08-07 05:39 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2017-08-15 15:14 |
|
Articles in Press |
|
2017-08-15 15:14 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2017-09-20 01:03 |
|
Publish the Manuscript Online |
|
2017-09-21 07:51 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told?
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Abhinav Vasudevan, Peter R Gibson and Daniel R van Langenberg |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Abhinav Vasudevan, BM BCh, Doctor, Doctor, Gastroenterology and Hepatology, Eastern Health and Monash University, Level 2, 5 Arnold Street, Box Hill Hospital, Box Hill 3128, Victoria, Australia. abhinav.vasudevan@gmail.com |
| Key Words |
Crohn’s disease; clinical pharmacology; ulcerative colitis; thiopurines; Inflammatory bowel disease; biologics; nutrition |
| Core Tip |
There appears to be marked variation in time to clinical response for therapies used in inflammatory bowel disease which is further influenced by disease and patient related factors. The most rapid response can be expected with corticosteroids, calcineurin inhibitors, exclusive enteral nutrition, aminosalicylates and anti-tumor necrosis factor therapy (within 2 mo), while methotrexate, thiopurines and vedolizumab can take several months to achieve maximal response. There is a lack of reporting of the time to response of therapies in clinical trials for inflammatory bowel disease and this remains an area that should be addressed in future studies. |
| Publish Date |
2017-09-21 07:51 |
| Citation |
Vasudevan A, Gibson PR, van Langenberg DR. Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told? World J Gastroenterol 2017; 23(35): 6385-6402 |
| URL |
http://www.wjgnet.com/1007-9327/full/v23/i35/6385.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v23.i35.6385 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
